1110 (1110) Fair Value & Analysis

Healthcare · Market cap HK$213M

1 1110 1110 · HK

PriceHK$0.3700

Fair ValueHK$0.4800

Upside+29.7%

Quality45/100

Evidence: Medium Range HK$0.3600 – HK$0.6000

Fair value as of: Jul 2, 2026

From 23 valuation models · updated today

Share price −12.9% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.3600 – HK$0.6200 · fair‑value band HK$0.3600 – HK$0.6000 · the HK$0.3700 price screens below the HK$0.4800 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1110 (1110) currently trades at HK$0.3700, while our model-based Fair Value estimate is HK$0.4800 — implying the stock looks roughly 29.7% undervalued today. We read business quality at 45/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

Over the trailing twelve months, 1110 generated revenue of HK$917M at a net margin of 1.2%. Revenue declined 4.2% year over year. It earns a return on equity of 5.6%. Net debt stands at HK$170M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$917M

Revenue growth (YoY) -4.2%

Net margin 1.2%

Return on equity 5.6%

Free cash flow HK$54.9M FY2025

P/E ratio 18.0

More key figures

Operating margin 9.1%

EPS (TTM) HK$-0.0100

EPS growth (YoY) +44.5%

Net debt HK$170M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1110 reported revenue of HK$917M in FY2025 versus HK$847M in FY2021, a compound +2.0%/yr. Reported net income was HK$11.3M in FY2025, compounding −21.9%/yr from FY2021.

Revenue +2.0%/yr

FY21 HK$847M

FY22 HK$958M

FY23 HK$1.1B

FY24 HK$1.1B

FY25 HK$917M

Net income −21.9%/yr

FY21 HK$30.3M

FY22 HK$22.7M

FY23 HK$38.1M

FY24 HK$41.6M

FY25 HK$11.3M

Is 1110 fairly valued? → Check now

Similar stocks

6 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
JD Health International Inc JDHIY	$5.33	$7.09	+33%
Alibaba Health Information Technology Limited ALBBY	$8.56	$6.91	-19%
0241 0241	HK$3.08	HK$2.04	-34%
Raia Drogasil S.A RADL3	R$17.46	R$16.13	-8%
Yifeng Pharmacy Chain Co 603939	¥20.91	¥22.00	+5%
Clicks Group CLCGY	$29.02	$34.57	+19%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1110 (1110) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.4800 versus a price of HK$0.3700 — about +30% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 1110?

Our model-based fair value for 1110 is HK$0.4800 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.3700.

What is the quality score of 1110?

1110 has a Quality Score of 45/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1110 (1110)?

1110 reported trailing-twelve-month revenue of about HK$917M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1110?

The net profit margin of 1110 is about 1.2%, meaning it keeps roughly 1.2% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.